Clinical Trial: Orelabrutinib Combined With Pola-R-CHP Regimen for the Treatment of Untreated Double-Expressor Diffuse Large B-Cell Lymphoma

U.S., July 23 -- ClinicalTrials.gov registry received information related to the study (NCT07078500) titled 'Orelabrutinib Combined With Pola-R-CHP Regimen for the Treatment of Untreated Double-Expressor Diffuse Large B-Cell Lymphoma' on July 13.

Brief Summary: Assess the preliminary efficacy and safety of orelabrutinib in combination with the Pola-R-CHP regimen for the treatment of treatment-naive double-expressor diffuse large B-cell lymphoma.

Study Start Date: May 05

Study Type: INTERVENTIONAL

Condition: Diffuse Large B-Cell Lymphoma (DLBCL)

Intervention: DRUG: orelabrutinib combined with the Pola-R-CHP regimen

Enrolled patients will receive six cycles of orelabrutinib in combination with the Pola-R-CHP regimen, with each 21-day ...